A Phase 3 interventional study of Abatacept and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 82 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-05.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is the only one that started in 2013, is one of 4 in phase 3, and was the 2nd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:
Bristol-Myers Squibb
Ages 4–75
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 489 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 203 across the 9 interventional studies, 38,396 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare subcutaneous Abatacept to placebo in the treatment of psoriatic arthritis
ASTRAEA=Active PSoriaTic ARthritis RAndomizEd TriAl
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Subjects at risk for tuberculosis (TB). Specifically, subjects with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
Drug: Abatacept
Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
Drug: Placebo
Also known as: Orencia
Proportion of ACR 20 Responders at Day 169
The American College of Rheumatology (ACR) 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
Time frame: Day 169
Proportion of Health Assessment Questionnaire (HAQ) Responders at Day 169
Participants were considered responders if their HAQ score decreased at least 0.35 from baseline. The number of HAQ responders was divided by the number of treated participants and expressed as a percentage. Scoring conventions are based on the Standard Disability Index of HAQ/HAQ-DI using the 20 response items. For each of the 8 disability categories there is an "aids/devices" companion variable that is used to record the type of assistance, if any, a participant uses for his/her usual activities. If either "aids/devices" and/or "assistance from another person" are checked for a disability category, the score for this category is set to "2" (much difficulty), if the original score was "0" (no difficulty) or "1" (some difficulty). The HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
Time frame: Baseline to Day 169
Proportion of ACR 20 Responders at Day 169 in the TNFi-naïve Subpopulation
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-naive participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
Time frame: Day 169
Proportion of ACR 20 Responders at Day 169 in the TNFi-exposed Subpopulation
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-exposed participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
Time frame: Day 169
Proportion of Non-progressors in Total PsA-modified SHS at Day 169
The number of radiographic non-progressors in total PsA-Modified Sharp van der Heijde score (SHS) at Day 169 was divided by the number of treated participants and expressed as a percentage. Non-progression was defined as a change from baseline in total PsA modified SHS ≤0. Early escape participants, and participants with missing data at day 169 were imputed as non-progressors.
Time frame: Baseline to Day 169
Proportion of Participants Achieving a PASI 50 at Day 169 in Participants With Baseline BSA >= 3%
The number of participants who achieved at least 50% improvement from baseline in Psoriasis Area and Severity Index Arthritis (PASI 50) at Day 169 was divided by the number of treated participants with BSA \>= 3% and expressed as a percentage. Only participants with \>= 3% body surface area (BSA) of psoriatic skin involvement at randomization were included in this analysis.
Time frame: Baseline to Day 169
Proportions of ACR 50 and ACR 70 Responders at Day 169
The ACR 50 and ACR 70 definition of improvement is a 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 50% or 70% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 50 and ACR 70 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
Time frame: Day 169
Mean Change From Baseline in SF-36 Physical and Mental Components at Day 169
Adjusted mean change in scores on the Short Form 36 physical and mental function assessment (SF-36) from baseline were analyzed from the physical component summary (PCS) mental component summary (MCS). The SF-36 is a participant questionnaire assessing 8 domains of health status: physical functioning, pain, vitality, social functioning, psychological functioning, general health perception, and role limitations due to physical and emotional problems. The instrument can be divided into two summary scores, physical and mental component score. The scores range from 0 to 100, with a higher score indicating better quality of life. The two summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales.
Time frame: Baseline to Day 169
Proportion of Participants With at Least One Positive Immunogenicity Response up to Day 169 Relative to Baseline
Blood samples were collected at Days 1, 85 and 169 and assayed for the presence of abatacept-specific antibodies. The number of participants with at least one positive immunogenicity response was divided by the number of treated participants and expressed as a percentage.
Time frame: Baseline to Day 169
Proportion of Participants With AEs at Day 169
Proportion of participants with AEs at Day 169
Time frame: Day 169
Proportion of Participants With SAEs at Day 169
Proportion of participants with SAEs at Day 169
Time frame: Day 169
Proportion of Participants With AEs Leading to Discontinuation at Day 169
Proportion of participants with AEs leading to discontinuation at Day 169
Time frame: Day 169
Proportion of Participant Deaths at Day 169
Proportion of participant deaths at Day 169
Time frame: Day 169
Proportion of Participants With Marked Laboratory Abnormalities at Day 169
Proportion of participants with marked laboratory abnormalities at Day 169
Time frame: Day 169
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 213 | 211 |
| Completed | 125 | 98 |
| Not completed | 88 | 113 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Lack of efficacy | 5 | 12 |
| Withdrew: Subject request to discontinue treatment | 2 | 3 |
| Withdrew: Withdrawal by subject | 3 | 5 |
| Withdrew: Subject no longer met criteria | 1 | 0 |
| Withdrew: Entered open-label in error | 0 | 1 |
| Withdrew: Early escape: transitioned to ol period | 76 | 89 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 197 | 185 |
| Completed | 169 | 166 |
| Not completed | 28 | 19 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Lack of efficacy | 16 | 8 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Subject request discontinue treatment | 4 | 3 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Other reasons | 1 | 1 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 106 | 0 |
| Completed | 81 | 0 |
| Not completed | 25 | 0 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Subject request to discontinue treatment | 10 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Subject withdrew consent | 7 | 0 |
The American College of Rheumatology (ACR) 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of ACR 20 Responders at Day 169 | 39.4 (32.9 to 46.0) | 22.3 (16.7 to 27.9) |
Participants were considered responders if their HAQ score decreased at least 0.35 from baseline. The number of HAQ responders was divided by the number of treated participants and expressed as a percentage. Scoring conventions are based on the Standard Disability Index of HAQ/HAQ-DI using the 20 response items. For each of the 8 disability categories there is an "aids/devices" companion variable that is used to record the type of assistance, if any, a participant uses for his/her usual activities. If either "aids/devices" and/or "assistance from another person" are checked for a disability category, the score for this category is set to "2" (much difficulty), if the original score was "0" (no difficulty) or "1" (some difficulty). The HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
| percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Health Assessment Questionnaire (HAQ) Responders at Day 169 | 31.0 (24.8 to 37.2) | 23.7 (18.0 to 29.4) |
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-naive participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of ACR 20 Responders at Day 169 in the TNFi-naïve Subpopulation | 44.0 (33.4 to 54.7) | 22.2 (13.2 to 31.3) |
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-exposed participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of ACR 20 Responders at Day 169 in the TNFi-exposed Subpopulation | 36.4 (28.1 to 44.7) | 22.3 (15.2 to 29.5) |
The number of radiographic non-progressors in total PsA-Modified Sharp van der Heijde score (SHS) at Day 169 was divided by the number of treated participants and expressed as a percentage. Non-progression was defined as a change from baseline in total PsA modified SHS ≤0. Early escape participants, and participants with missing data at day 169 were imputed as non-progressors.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Non-progressors in Total PsA-modified SHS at Day 169 | 42.7 (36.1 to 49.4) | 32.7 (26.4 to 39.0) |
The number of participants who achieved at least 50% improvement from baseline in Psoriasis Area and Severity Index Arthritis (PASI 50) at Day 169 was divided by the number of treated participants with BSA \>= 3% and expressed as a percentage. Only participants with \>= 3% body surface area (BSA) of psoriatic skin involvement at randomization were included in this analysis.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Participants Achieving a PASI 50 at Day 169 in Participants With Baseline BSA >= 3% | 26.7 (19.5 to 33.9) | 19.6 (13.2 to 26.0) |
The ACR 50 and ACR 70 definition of improvement is a 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 50% or 70% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 50 and ACR 70 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| ACR 50 | 19.2 (14.0 to 24.5) | 12.3 (7.9 to 16.8) |
| ACR 70 | 10.3 (6.2 to 14.4) | 6.6 (3.3 to 10.0) |
Adjusted mean change in scores on the Short Form 36 physical and mental function assessment (SF-36) from baseline were analyzed from the physical component summary (PCS) mental component summary (MCS). The SF-36 is a participant questionnaire assessing 8 domains of health status: physical functioning, pain, vitality, social functioning, psychological functioning, general health perception, and role limitations due to physical and emotional problems. The instrument can be divided into two summary scores, physical and mental component score. The scores range from 0 to 100, with a higher score indicating better quality of life. The two summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales.
| SF-36 points | Abatacept | Placebo |
|---|---|---|
| PCS | 5.11 ± 0.637 | 3.69 ± 0.707 |
| MCS | 2.56 ± 0.826 | 2.62 ± 0.924 |
Blood samples were collected at Days 1, 85 and 169 and assayed for the presence of abatacept-specific antibodies. The number of participants with at least one positive immunogenicity response was divided by the number of treated participants and expressed as a percentage.
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Participants With at Least One Positive Immunogenicity Response up to Day 169 Relative to Baseline | 3.9 | 8.6 |
Proportion of participants with AEs at Day 169
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Participants With AEs at Day 169 | 54.5 | 53.1 |
Proportion of participants with SAEs at Day 169
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Participants With SAEs at Day 169 | 2.8 | 4.3 |
Proportion of participants with AEs leading to discontinuation at Day 169
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Participants With AEs Leading to Discontinuation at Day 169 | 1.4 | 1.9 |
Proportion of participant deaths at Day 169
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Participant Deaths at Day 169 | 0 | 0 |
Proportion of participants with marked laboratory abnormalities at Day 169
| Percentage of participants | Abatacept | Placebo |
|---|---|---|
| Proportion of Participants With Marked Laboratory Abnormalities at Day 169 | 3.2 | 5.4 |
Collected over Up to 56 days post last dose in the short-term period or the first dose in the open-label period, whichever occurs first. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABATACEPT DURING DOUBLE-BLIND PERIOD | 0/213 (0%) | 6/213 (2.8%) | 39/213 (18.3%) |
| PLACEBO DURING DOUBLE-BLIND PERIOD | 0/211 (0%) | 9/211 (4.3%) | 43/211 (20.4%) |
| ABATACEPT DURING OPEN-LABEL PERIOD | 0/382 (0%) | 29/382 (7.6%) | 92/382 (24.1%) |
| ABATACEPT DURING OPEN-LABEL EXTENSION PERIOD | 0/322 (0%) | 20/322 (6.2%) | 103/322 (32%) |
| ABATACEPT DURING LONG-TERM EXTENSION PERIOD | 0/106 (0%) | 17/106 (16%) | 56/106 (52.8%) |
| Event | ABATACEPT DURING DOUBLE-BLIND PERIOD | PLACEBO DURING DOUBLE-BLIND PERIOD | ABATACEPT DURING OPEN-LABEL PERIOD | ABATACEPT DURING OPEN-LABEL EXTENSION PERIOD | ABATACEPT DURING LONG-TERM EXTENSION PERIOD |
|---|---|---|---|---|---|
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 0/213 | 1/211 | 2/382 | 3/322 | 3/106 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/213 | 0/211 | 0/382 | 4/322 | 2/106 |
| Abdominal painGastrointestinal disorders | 0/213 | 0/211 | 0/382 | 0/322 | 1/106 |
| Pancreatitis acuteGastrointestinal disorders | 0/213 | 0/211 | 0/382 | 0/322 | 1/106 |
| Cholecystitis acuteHepatobiliary disorders | 0/213 | 1/211 | 1/382 | 1/322 | 1/106 |
| Hepatic fibrosisHepatobiliary disorders | 0/213 | 0/211 | 0/382 | 0/322 | 1/106 |
| GastroenteritisInfections and infestations | 2/213 | 0/211 | 0/382 | 0/322 | 1/106 |
| Groin abscessInfections and infestations | 0/213 | 0/211 | 0/382 | 0/322 | 1/106 |
| Tooth abscessInfections and infestations | 0/213 | 0/211 | 0/382 | 0/322 | 1/106 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/213 | 0/211 | 0/382 | 0/322 | 1/106 |
| Event | ABATACEPT DURING DOUBLE-BLIND PERIOD | PLACEBO DURING DOUBLE-BLIND PERIOD | ABATACEPT DURING OPEN-LABEL PERIOD | ABATACEPT DURING OPEN-LABEL EXTENSION PERIOD | ABATACEPT DURING LONG-TERM EXTENSION PERIOD |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/213 | 11/211 | 17/382 | 26/322 | 16/106 |
| BronchitisInfections and infestations | 7/213 | 5/211 | 19/382 | 17/322 | 15/106 |
| Back painMusculoskeletal and connective tissue disorders | 4/213 | 2/211 | 10/382 | 11/322 | 12/106 |
| CatarrhRespiratory, thoracic and mediastinal disorders | 1/213 | 0/211 | 1/382 | 2/322 | 12/106 |
| HypertensionVascular disorders | 5/213 | 8/211 | 10/382 | 7/322 | 9/106 |
| Urinary tract infectionInfections and infestations | 10/213 | 2/211 | 10/382 | 12/322 | 8/106 |
| Upper respiratory tract infectionInfections and infestations | 6/213 | 14/211 | 23/382 | 19/322 | 3/106 |
| PharyngitisInfections and infestations | 0/213 | 2/211 | 5/382 | 10/322 | 6/106 |
| SciaticaNervous system disorders | 1/213 | 0/211 | 2/382 | 1/322 | 6/106 |
| InfluenzaInfections and infestations | 4/213 | 3/211 | 9/382 | 17/322 | 4/106 |
All randomized participants
| Age, Continuous(years) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 51.0 ± 10.67 | 49.8 ± 11.26 | 50.4 ± 10.97 |
| Sex: Female, Male(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Female | 121 | 112 | 233 |
| Male | 92 | 99 | 191 |
| Race (NIH/OMB)(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 195 | 198 | 393 |
| More than one race | 18 | 11 | 29 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2013 to primary completion in Jul 2015, 24 months.
Results were first posted in Aug 2017, 2 years after primary completion. A results delay was requested in Jun 2016.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 24 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept